Current status and future prospects of chemotherapy for metastatic gastric cancer: a review
- PMID: 15864716
- DOI: 10.1007/s10120-005-0324-9
Current status and future prospects of chemotherapy for metastatic gastric cancer: a review
Abstract
Although many randomized trials of chemotherapy for metastatic gastric cancer have been reported during the past two decades, no standard regimens worldwide have been established yet. Reference arms vary depending on the region and cultural differences. To date, a combination of 5-fluorouracil (5-FU) and cisplatin is most widely used. However, no confirmation of survival advantage over single-agent 5-FU in a randomized trial has been proved yet, and there remain limitations of efficacy results in older-generation regimens. Recently developed new agents such as irinotecan, taxanes (paclitaxel and docetaxel), and new oral fluorouracil (S-1 and capecitabine) provided more promising results: a response rate over 50% and median survival time (MST) over 10 months in their preliminary combination studies. These newer combination regimens are now being investigated in various randomized phase III studies, which will clarify whether the newer-generation regimens provide survival advantage over older-generation regimens. The MST of the new standard should exceed 11 months to be considered a definite improvement, and overall survival seems to be a more desirable primary end point than progression-free survival in a randomized trial. Molecular targeting agents are another concern to improve the treatment outcomes of this disease and are now under investigation in combination with conventional cytotoxic agents. Both clinical and biological research will be more important in future studies.
Similar articles
-
Developments in the treatment of gastric cancer in Europe.Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):22-5. Oncology (Williston Park). 2000. PMID: 11200144 Review.
-
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28. Cancer Chemother Pharmacol. 2011. PMID: 20878159 Clinical Trial.
-
Docetaxel in the treatment of gastric cancer.Future Oncol. 2006 Oct;2(5):603-20. doi: 10.2217/14796694.2.5.603. Future Oncol. 2006. PMID: 17026452 Review.
-
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.Anticancer Res. 2012 Sep;32(9):4151-6. Anticancer Res. 2012. PMID: 22993377 Clinical Trial.
-
Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.Chemotherapy. 2011;57(3):230-5. doi: 10.1159/000327840. Epub 2011 May 18. Chemotherapy. 2011. PMID: 21597287
Cited by
-
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.BMC Cancer. 2008 Jul 25;8:210. doi: 10.1186/1471-2407-8-210. BMC Cancer. 2008. PMID: 18652704 Free PMC article.
-
Chemotherapy for gastric cancer in Japan.Int J Clin Oncol. 2008 Jun;13(3):191-2. doi: 10.1007/s10147-008-0790-2. Epub 2008 Jun 14. Int J Clin Oncol. 2008. PMID: 18553225 No abstract available.
-
B7-H3 promotes gastric cancer cell migration and invasion.Oncotarget. 2017 May 13;8(42):71725-71735. doi: 10.18632/oncotarget.17847. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069741 Free PMC article.
-
SPOCK: Master regulator of malignant tumors (Review).Mol Med Rep. 2024 Dec;30(6):231. doi: 10.3892/mmr.2024.13355. Epub 2024 Oct 11. Mol Med Rep. 2024. PMID: 39392048 Free PMC article. Review.
-
A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Br J Cancer. 2010 Oct 26;103(9):1343-8. doi: 10.1038/sj.bjc.6605928. Epub 2010 Oct 5. Br J Cancer. 2010. PMID: 20924378 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous